VDFF is an innovative measurement tool integrated into the Velacur® software that combines quantitative measures of ultrasound attenuation and backscatter.
VDFF has an outstanding accuracy (AUC) of 95% as a classifier of patients with more than 5% MRI-PDFF, a definition for the presence of hepatic steatosis.
*Data from validation cohort Honavar; Lobo; Schneider; et al., 2024
*Data from parameter fitting cohort Honavar; Lobo; Schneider; et al., 2024
Backscatter
Fat increases the reflection of ultrasound signals back towards the probe, increasing the brightness of the image The brighter the image, the higher the fat content
Attenuation
Fat scatters ultrasound signals, reducing the amplitude of the ultrasound signals reflected back to the probe as they travel through the liver The more the amplitude of the ultrasound signal decreases as it travels through the liver, the higher the attenuation.
Julia PinterMarketing Director
Julia Pinter brings over a decade of medical technology marketing experience spanning product commercialization, launch strategy, and sales enablement. Prior to joining Sonic Incytes, she served as Director of Global GI Product Marketing at PENTAX Medical, where she led global downstream marketing for the company’s largest portfolio — driving commercial launches of next-generation endoscopes, imaging systems, and AI platforms across the Americas, Europe, and Asia-Pacific. At Sonic Incytes, Julia leads downstream marketing initiatives to expand awareness and accelerate adoption of Velacur One®, translating its clinical and economic value into programs that support broader adoption of non-invasive liver assessment.